The founders of the Brian Piccolo Cancer Research Fund understood that too often, medical research and patient care exist in separate worlds.
The founders of the Brian Piccolo Cancer Research Fund understood that too often, medical research and patient care exist in separate worlds. That’s why the fund chooses to invest in translational research that pushes new therapies from the laboratory to the patient’s bedside while also using observations in the clinic to inform research. As compared to basic science research, translational research shortens the timeframe for the actual application of laboratory findings.
The Piccolo Fund has chosen to focus priority on women’s cancers since 1991, and investments in breast, ovarian and lung cancer research have resulted in diagnostic tools that detect cancer earlier, more targeted treatments, and chemotherapy protocols that are better tolerated by patients.
We are now on the verge of delivering personalized cancer treatment based on a patient’s own genetic make-up. This is an exciting and important advance, one that founders like the Piccolo Fund have helped make possible.